TYK Medicines Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	-	0.11	-	44.24
Cost of Revenue	-	0.09	-	24.2
Gross Profit	-	0.01	-	20.04
Selling, General & Admin	78.48	108.33	59.31	33.54
Research & Development	244.06	235.45	249.25	229.81
Operating Expenses	322.54	343.78	308.56	263.35
Operating Income	-322.54	-343.76	-308.56	-243.31
Interest Expense	-14.92	-12.57	-8.73	-3.26
Interest & Investment Income	2.74	3.28	3.73	7.37
Currency Exchange Gain (Loss)	5.12	0.29	0.1	-
Other Non Operating Income (Expenses)	20.92	-35.21	-68.98	-72.87
EBT Excluding Unusual Items	-308.69	-387.97	-382.44	-312.06
Gain (Loss) on Sale of Investments	-	-0	-0.73	0.34
Gain (Loss) on Sale of Assets	-	0.04	-0.01	-0.04
Other Unusual Items	2.71	0	0.01	-0.05
Pretax Income	-305.97	-387.93	-383.17	-311.8
Earnings From Continuing Operations	-305.97	-387.93	-383.17	-311.8
Minority Interest in Earnings	6.2	0.97	0.74	0.81
Net Income	-299.77	-386.96	-382.43	-310.99
Net Income to Common	-299.77	-386.96	-382.43	-310.99
Shares Outstanding (Basic)	375	338	289	278
Shares Outstanding (Diluted)	375	338	289	278
Shares Change (YoY)	10.94%	16.91%	3.94%	-
EPS (Basic)	-0.80	-1.15	-1.32	-1.12
EPS (Diluted)	-0.80	-1.15	-1.32	-1.12
Free Cash Flow	-	-381.87	-277.32	-279.02
Free Cash Flow Per Share	-	-1.13	-0.96	-1.00
Gross Margin	-	13.08%	-	45.30%
Operating Margin	-	-321274.77%	-	-549.94%
Profit Margin	-	-361640.19%	-	-702.94%
Free Cash Flow Margin	-	-356891.59%	-	-630.67%
EBITDA	-307.61	-328.83	-295.1	-232.31
D&A For EBITDA	14.93	14.93	13.46	11
EBIT	-322.54	-343.76	-308.56	-243.31

Source: S&P Global Market Intelligence. Standard template. Financial Sources.